Welcome to our dedicated page for Absci news (Ticker: ABSI), a resource for investors and traders seeking the latest updates and insights on Absci stock.
Absci Corporation (Nasdaq: ABSI) is a clinical-stage biopharmaceutical and biotechnology company that frequently issues news related to its generative AI-driven drug discovery platform and internal pipeline of biologic therapeutics. News coverage for Absci often centers on developments in its lead AI-designed antibody programs, platform collaborations, and corporate updates that are relevant to investors and the broader life sciences community.
A major focus of recent Absci news is ABS-201™, an anti-prolactin receptor (PRLR) antibody being developed for androgenetic alopecia and investigated for endometriosis. Press releases have described preclinical human ex vivo data on hair growth, the design and initiation of the Phase 1/2a HEADLINE trial in androgenetic alopecia, and plans for Phase 2 development in endometriosis. Updates also highlight scientific advisory board appointments, key opinion leader seminars, and partnerships aimed at elevating patient perspectives in hair loss research.
Investors following ABSI news can also expect announcements on pipeline progress for programs such as ABS-101, ABS-301, and ABS-501, as well as drug creation partnerships with pharmaceutical, biotech, technology, and academic organizations. Absci has reported collaborations with cloud and hardware providers to support its AI Drug Creation platform, along with participation in healthcare and biotech investor conferences and major industry events.
This news feed aggregates Absci’s press releases and third-party coverage, including items on clinical trial milestones, scientific data presentations, financing and capital markets activity, and corporate governance changes. Readers interested in ABSI can use this page to monitor how Absci’s AI-enabled platform, internal therapeutic programs, and partnerships evolve over time and to track key events that may shape the company’s scientific and business trajectory.
Absci Corporation (Nasdaq: ABSI) announced that CEO Sean McClain will participate in the Synthetic Biology Enabling Drug Discovery Panel at the Cowen 42nd Annual Health Care Conference. The event is set for March 8, 2022, from 12:30-1:30 p.m. Pacific Time / 3:30-4:30 p.m. Eastern Time. A live and archived webcast will be available on the company’s investor relations website.
Absci leverages deep learning AI and synthetic biology in drug discovery, aiming to advance the therapeutic potential of proteins.
Absci Corporation (Nasdaq: ABSI), a pioneer in drug and target discovery utilizing deep learning AI, announced its participation in two upcoming virtual investor conferences. The Truist Life Sciences AI Symposium will feature a panel discussion on March 1, 2022, at 7:10 a.m. PT, while the Cowen 42nd Annual Health Care Conference will include a fireside chat on March 7, 2022, at 9:50 a.m. PT. Interested attendees can access these events through the provided links. These engagements highlight Absci's commitment to expanding the therapeutic potential of proteins and facilitating drug development.
Absci Corporation (Nasdaq: ABSI) will participate virtually in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15, 2022, at 8:30 a.m. Pacific Time. The company specializes in drug and target discovery by leveraging deep learning AI and synthetic biology, aiming to enhance the therapeutic potential of proteins. Absci's Integrated Drug Creation™ Platform allows the identification of novel drug targets and the discovery of optimal biotherapeutic candidates in a streamlined process. For more information, visit www.absci.com.
Absci Corporation (Nasdaq: ABSI) has announced a research collaboration with Merck to utilize its AI-driven Integrated Drug Creation™ Platform. This partnership will employ Absci's Bionic Protein™ technology to develop tailored enzymes for Merck's biomanufacturing needs. Absci can earn up to $610 million in milestone payments for three nominated drug targets, along with ongoing research funding and tiered royalties on sales. The collaboration aims to enhance the therapeutic potential of proteins and improve patient outcomes.
Absci Corporation (Nasdaq: ABSI) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference, scheduled for January 10th at 12:45 p.m. PT / 3:45 p.m. ET. This presentation will be conducted virtually, and interested individuals can access a live and archived webcast through the company's website.
Absci specializes in drug and target discovery using deep learning AI and synthetic biology, aiming to advance protein therapeutic potential. For more information, visit www.absci.com.
Absci Corporation (Nasdaq: ABSI) announced its participation in the H.C. Wainwright BIOCONNECT Virtual Conference on January 10th, 2022, at 4:00 a.m. Pacific Time. The company utilizes deep learning AI and synthetic biology for drug and target discovery, facilitating the development of protein-based drugs. Interested individuals can access the live and archived webcast through the investors' section on their website. With a focus on expanding therapeutic potential, Absci aims to transform innovative ideas into effective medicines.
Absci Corporation (Nasdaq: ABSI) will participate virtually in the 40th Annual J.P. Morgan Healthcare Conference on January 10th, 2022, at 7:30 a.m. PT/10:30 a.m. ET. The presentation will be accessible via a live and archived webcast on the company's website. Absci is known for its Integrated Drug Creation™ Platform, which leverages deep learning AI and synthetic biology to discover new drug targets and biotherapeutic candidates. The company aims to revolutionize drug development and enhance therapeutic options for patients.
Absci Corporation (Nasdaq: ABSI) reported its Q3 2021 financial results, showcasing promising growth and strategic developments. Revenue increased to $1.5 million from $0.9 million year-over-year. Research and development expenses surged to $10.7 million, reflecting investments in platform expansion, while selling, general, and administrative expenses rose to $9.7 million. The net loss widened to $23.6 million, including a $3.6 million non-cash charge. Absci maintains a robust cash position of $279.3 million, bolstered by its recent IPO, which raised approximately $210 million.
Absci Corporation (Nasdaq: ABSI), a leader in drug and target discovery utilizing deep learning AI and synthetic biology, announced its participation in two upcoming virtual investor conferences. The Credit Suisse 30th Annual Healthcare Conference will feature a fireside chat on November 9 at 10:00 a.m. PT, while the Stifel 2021 Virtual Healthcare Conference will host a fireside chat on November 16 at 1:40 p.m. PT. Interested parties can access webcasts of the presentations on the company's website.
Absci Corporation (Nasdaq: ABSI) has announced the opening of a new campus in Vancouver, Washington, expanding its operational capacity to accelerate the discovery and development of biologic drugs. The facility spans over 85,000 square feet, designed to enhance laboratory and office space for improved productivity. The new campus will triple the company's capacity for program execution and integrate advanced technologies for drug discovery. Washington Governor Jay Inslee praised Absci for its positive community impact and commitment to innovation in biotechnology.
FAQ
What is the current stock price of Absci (ABSI)?
What is the market cap of Absci (ABSI)?
